Laboratory testing is crucial for maintaining the safety and nutritional value of animal feed throughout the food chain. Labs leverage Laboratory Information Management Systems (LIMS) to enhance traceability and efficiency, meeting regulatory standards and consumer demands. From production to R&D and public health, this article explores the diverse roles of feed testing labs and the specialized LIMS features they require. [Read More]

All digital transformations need to start somewhere. It’s often recommended to start small when making a change of this magnitude. LabTwin, the voice-powered and AI-enabled digital laboratory assistant, is a good choice for beginning your digital transformation. It’s a low-cost solution with little-to-no down-time for implementation and a rapid learning curve. Despite its ease of deployment, it makes an outsize impact on daily operations through the transformational change that comes with a digital lab assistant. [Read More]

Laboratory information management plays a vital role in the accuracy and reliability of testing results. Since the bygone days of spreadsheets and filing systems, laboratory technology has advanced significantly. Labs today supply researchers and technicians with sophisticated digital tools that support them throughout the testing process, from sample processing to results reporting. Which is the appropriate laboratory information software for your lab? [Read More]

Human errors, poor productivity and inefficient collaboration between team members in a laboratory can cause serious issues. Luckily, with the help of modern technology, barcoding offers a solution. These barcodes can easily be printed in the form of a sticker and used to label various items inside your lab. However, it’s important to understand the function and benefits of this strategy within laboratory workflows. [Read More]

Autoscribe has released a new case study with CIA Labs that highlights how Matrix LIMS has streamlined their approval process, reduced the burden of paperwork, and improved their overall turn-around times. [Read More]

In recent years, the medical cannabis industry has experienced significant growth and acceptance worldwide. With this growth comes the need for robust and efficient systems to manage the complex processes involved in cannabis cultivation, processing, and distribution. This is where Laboratory Information Management Systems (LIMS) play a crucial role. In this blog post, we will dive into the LIMS in the Medical Cannabis industry together.  LIMS in the medical cannabis industry serve as a comprehensive solution for managing laboratory workflows, data, and compliance requirements.  [Read More]

Enhance your lab's efficiency and data integrity with the powerful integration of Laboratory Execution Systems (LES) and Electronic Lab Notebooks (ELN) offered by LabLynx LIMS. This comprehensive solution streamlines workflows, ensures compliance, and improves collaboration within your laboratory environment. [Read More]

In this "in press" journal article published in Practical Laboratory Medicine, Smith et al. of ARUP Laboratories provide the results of a survey conducted just prior to the U.S. Food and Drug Administration's (FDA's) April 29 release of their final rule on laboratory-developed tests (LDTs). Polling a select group of its clinical laboratory customers, the authors sought to discover clinical laboratorians' opinions about the then proposed changes to regulate LDTs as medical devices. The survey was conducted in part due to a set of perceived FDA shortcomings that would make it "difficult for the FDA to conduct an accurate quantitative analysis of public opinion in a key sector directly impacted by its proposed rule." The authors describe the structure of their survey and its associated analytical methods before discussing the results. They then provides a full discussion with a brief conclusion: "The majority of clinical laboratorians surveyed do not support the FDA’s proposed rule on LDTs and report having insufficient resources to comply with the rule if it is enacted," and that the FDA had more work to do "to better understand the negative impacts of the proposed rule."